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Abstract
Background—Given high rates of HIV among Baltimore MSM, we examined characteristics 
associated with HIV prevalence and unrecognized HIV infection among Baltimore MSM at two 
time points.
Methods—Cross-sectional behavioral surveys and HIV testing in 2004–2005 and 2008 using 
venue-based sampling among adult Baltimore men at MSM-identified locations. MSM was 
defined as sex with a male partner in the past year. Bivariate and backwards stepwise regression 
identified characteristics associated with HIV and unrecognized infection.
Findings—HIV prevalence was 37.7% overall in 2004–2005 (n=645) and 37.5% in 2008 
(n=448), 51.4% and 44.7% among Black MSM, and 12.9% and 18.3% among non-Hispanic White 
MSM. Compared to non-Hispanic White MSM, Black MSM were 4.0 times (95% C.I.: 2.3, 7.0) 
more likely to be HIV-positive in 2004–2005 and 2.5 times (95% C.I.: 1.5, 4.0) more likely in 
2008. Prevalence of unrecognized HIV infection was 58.4% overall in 2004–2005 and 74.4% in 
2008, 63.8% and 76.9% among Black MSM, and 15.4% and 47.4% among non-Hispanic White 
MSM. In adjusted models, unrecognized infection was significantly associated with minority race/
ethnicity, younger age, and no prior year doctor visits in 2004–5 and with younger age and no 
prior year doctor visits in 2008.
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Conclusion—High rates of HIV infection and substantial rates of unrecognized HIV infection 
among Baltimore MSM, particularly men of color and young men, require urgent public and 
private sector attention and increased prevention response.
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Introduction
Since the late 1990s, the gay community’s early success in initiating risk reduction behavior 
change and slowing the rate of new cases of HIV/AIDS1–3 has been overshadowed by 
evidence of a resurgence of HIV/AIDS among men who have sex with men (MSM) in the 
United States. HIV infection rates among MSM have climbed steadily since the early 1990s, 
now accounting for more than half of new infections4. The rate of new HIV diagnosis 
among MSM is 44 times higher compared to non-MSM men5.
Throughout the MSM HIV/AIDS epidemic, Black men have been at particular risk. In 1986, 
nearly 15 percent of cumulative AIDS cases in homosexual and bisexual men occurred 
among Black men6. By the end of 2007, Black MSM comprised more than a quarter of the 
cumulative reported AIDS cases among MSM7 and 35% of new infections among MSM 
were among African-Americans8.
Maryland had the second highest estimated AIDS diagnosis rate in the United States in 
20089. Baltimore is the location hardest hit by HIV/AIDS in Maryland, accounting for 78% 
of prevalence in the central region. MSM account for 24% of HIV/AIDS prevalence and 
represent the only transmission category in central Maryland for which HIV incidence is 
increasing10.
There are more new HIV infections among African-American MSM aged 13–29 than any 
other age or race/ethnic group8. In Maryland, 1 in 5 African-American MSM are estimated 
to be HIV positive, compared to 1 in 24 Hispanic/Latino MSM and 1 in 38 White MSM 11. 
The Young Men’s Survey showed that young Black MSM in Baltimore had the highest 
percent prevalence of HIV infection, HIV incidence12, and unrecognized HIV infection13 
among seven participating cities.
The CDC National HIV Behavioral Surveillance System (NHBS) collects behavioral data 
among populations at high risk for HIV, including MSM, in selected U.S. areas with high 
HIV prevalence14. Recently released 2008 findings show that 19% of MSM are HIV positive 
and 44% of HIV positive men are unaware of their HIV status nationwide15. HIV prevalence 
and unrecognized HIV infection was highest among Black MSM. Among participating 
cities, HIV prevalence ranged from 6% in Atlanta to 39% in Baltimore. Unrecognized 
infection ranged from 15% in Seattle to 73% in Baltimore. These high rates of HIV and 
unrecognized infection among Baltimore MSM further bolster a need to understand social 
and behavioral correlates of HIV in this city.
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Research among young MSM in Baltimore shows strong racial disparities in HIV 
infection 16,17 and HIV incidence 18. Older age, recent STD diagnosis, and high numbers of 
sex partners have also been associated with HIV among young Baltimore MSM 16. It is 
unknown whether these findings can be generalized to the larger community of MSM in 
Baltimore. Additionally, little is known about factors associated with unrecognized HIV 
infection in this population. The NHBS project, known as the Behavioral Surveillance 
Research (BESURE) Study in Baltimore, recruited MSM in 2005 and 2008. Using data from 
both BESURE MSM waves, the current paper examined the extent of racial disparity and 
correlates of HIV prevalence and awareness of HIV seropositivity at each time point.
Methods
Sampling Design and Recruitment
The BESURE Study (NHBS Baltimore) is an HIV infection and behavioral risk cross-
sectional survey among populations at high risk for HIV. The methods and sampling for 
NHBS-MSM have been previously described in detail15,19. Two serial cross-sectional waves 
of venue-based data collection were conducted among MSM in Baltimore. The first was 
conducted between June 2004 and April 2005 and the second between July and October 
2008. Study protocols for both waves were identical.
Formative research included focus groups with MSM and interviews with community 
informants and public health practitioners to identify current public and private venues (e.g., 
bars, clubs, businesses, events, neighborhood locations) frequently attended by Baltimore 
MSM and high-traffic day/time periods for recruitment. Sampling frames were subsequently 
constructed from the universe of venues and their corresponding day/time periods, and 15 or 
more venue-day-time periods (i.e., sampling events) were randomly selected and scheduled 
for recruitment each month. Sampling events averaged 18 per month in both waves.
During each sampling event, study recruiters consecutively approached men who crossed a 
predetermined intercept area at the venue and assessed eligibility. Eligible participants were: 
males 18 years or older, Baltimore-Towson metropolitan area residents, and had not 
previously participated in the current data collection wave; sexual identity or practice did not 
preclude men from being eligible. Eligible men completed study procedures either in a 
nearby mobile unit or in study offices at another scheduled time. All study procedures were 
anonymous. Consent was provided orally and documented in writing by trained 
interviewers. Consent for HIV testing was provided separately and not required for study 
participation in either wave. After completing informed consent procedures, participants 
were interviewed using a handheld computer-assisted standard questionnaire, provided a 
serum sample for HIV testing, received counseling and referral to prevention services, and 
received US$50.00 as reimbursement for their time. Follow-up appointments were scheduled 
within two weeks for HIV test results, post-test counseling, and referral to care or services as 
appropriate. The protocol and all study materials were reviewed and approved by the 
Maryland Department of Health and Mental Hygiene and the Johns Hopkins Bloomberg 
School of Public Health Institutional Review Boards.
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Measures
The standardized questionnaire included demographics, HIV-related risk behaviors, medical 
history, and sexual identity. Race/ethnicity categories were non-Hispanic White, Black, 
Hispanic, Native American, Pacific Islander, Asian-American or of mixed race (i.e., 
participants who reported being of more than one racial/ethnic ancestry). Since small 
numbers of Hispanic, Native American, Pacific Islander, Asian-American, or mixed race 
participants precluded detailed analysis, a single category called ‘Other race’ was created in 
addition to categories for non-Hispanic White and Black. Age was categorized to reflect 
quartiles of the age distribution of study participants. Being currently homeless was 
examined as a binary variable, whereas education was reported as the level attained at the 
time of the survey.
Participants were asked about HIV risk behaviors over their lifetimes and in the prior year. 
Recent sexual risk behaviors included number of male sexual partners (categorized to reflect 
quartiles of number of partners), sex with men only or sex with men and women, and 
unprotected anal intercourse (UAI). UAI was defined as not using a condom during one or 
more sex acts in the prior 12 months and categorized as ‘No UAI’, UAI only with a main 
male sexual partner, or UAI with at least one casual or exchange (i.e., sex in exchange for 
money or goods) male sexual partner. Lifetime variables included having received a prior 
HIV test, having injected illicit drugs and having had an STD diagnosis. Behaviors in the 
past year included having used non-prescribed drugs and having visited a doctor’s office. 
Finally, participants reported whether they had no, public, or private insurance coverage.
Blood specimens with sufficient volume were tested for HIV-1 antibodies by the Maryland 
Department of Health and Mental Hygiene Laboratories Administration with a U.S. Food 
and Drug Administration-licensed enzyme immunoassay (EIA) (Sanofi Diagnostics Pasteur, 
Chaska, MN, U.S.A.). The Maryland DHMH lab confirmed repeatedly reactive samples 
using Western blot (WB) (Bio-Rad, Hercules, CA, U.S.A. or Epitope, Inc., Organon-Teknika 
Corporation, Durham, NC, U.S.A.). An HIV-seropositive individual was defined as having a 
reactive EIA with a positive WB confirmation. Three respondents with indeterminant test 
results were excluded from the analysis. Unrecognized HIV infection was defined as having 
a confirmed HIV positive BESURE Study test and either reporting a negative or an unknown 
prior HIV test result during the survey. This category also included three respondents who 
refused to report results of their most recent test in the second wave.
Statistical Methods
Sample characteristics between wave 1 and wave 2 were compared using the chi-square 
statistic. Analyses with HIV positivity as the outcome were restricted to the 645 men and 
448 men who reported a same-sex experience within the past year in the first and second 
cross-sectional waves, respectively, and whose HIV test results were definitive. Analyses of 
unrecognized HIV infection were restricted to the 243 MSM and 168 MSM who tested HIV 
positive in the first and second cross-sectional waves, respectively. We assessed patterns of 
attendance at venues types included in the sampling frame. There was no association 
between frequency of venue attendance and the two outcomes of interest and data are 
presented and analyzed without weights.
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Associations between demographic variables and HIV risk behaviors with HIV prevalence 
and HIV unrecognized infection were assessed using the chi-square statistic. Unadjusted 
prevalence ratios (PR) were calculated with corresponding 95% confidence intervals (95% 
CI) using SAS PROC GENMOD’s log-binomial regression capability with a binomial 
distribution and a logarithmic link function21. Variables that showed a significant association 
with HIV prevalence or with HIV unrecognized infection (p ≤ 0.05) were analyzed using the 
COPY method to directly estimate adjusted prevalence ratios (APR) with their 
corresponding 95% CI 22. Both unadjusted and adjusted PROC GENMOD analyses used the 
REPEATED statement to account for clustering by venue. The PR was deemed as a more 
appropriate measure of association and a better approximation of the relative risk since the 
frequency of both outcomes exceeded 15%23,24. We arrived at the most parsimonious model 
by removing variables that were insignificant (P > 0.05) using a backwards stepwise 
approach and as determined by the likelihood ratio test. QIC was used to assess model fit. 
All statistical analyses were performed using Statistical Analysis Software (SAS) version 
9.1.
Results
Participant and sample characteristics
Figure 1 shows recruitment and venue information for both waves. During the first cross-
sectional wave (2004–2005), 1,296 men were approached to participate. After eligibility and 
enrollment, 891 had complete survey and serologic information and 645 reported a same-sex 
experience in the year prior to the survey (Figure 1). Eligible participants were recruited 
from 74 venues with mean venue sample size of 8.3 (SD: 14.6; range 1–88). During the 
second cross-sectional wave (2008), 1,326 men were approached for participation. After 
eligibility and enrollment, 600 participants had complete survey and serologic information 
and 448 reported prior year same-sex experience (Figure 1). In wave 2, eligible participants 
were recruited from 31 venues with mean venue sample size of 13.6 (SD: 9.0; range 2–35).
The demographic and HIV risk behavior composition of the two samples from the two 
waves differed (Table 1). Compared with the first cross-sectional wave, the second cross-
sectional wave was more likely to enroll MSM who reported: Black race; being less than 24 
years of age; homelessness; having had 2–3 male sexual partners in the past year; having had 
male sexual partners only; not having had UAI; using non-injection drugs in the past year; 
and lifetime drug injection. The two samples did not statistically differ in educational 
attainment, ever receiving an HIV test, ever receiving an STI diagnosis, health insurance 
status, or past year doctor visits.
In the first cross-sectional wave, median age was 34 years (range: 18–69), 70% were of 
minority race, and more than half reported post-secondary education. Most reported being 
homosexual/gay (63%), never injecting illegal drugs (83%), no STD diagnosis (84%), and 
had been tested for HIV (87%). In the prior year, 67% had sex with men only and 74% had 
more than one same-sex partner. About half reported using non-injected illegal drugs of 
which marijuana (76%) was most common, followed by cocaine (47%), and crack cocaine 
(25%). Approximately 60% had some form of health insurance and 77% had visited a doctor 
in the past year. Median time since last HIV test was 276 days.
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In the second cross-sectional study, median age was 30 (range: 18–72), 77% were of 
minority race, and more than half reported post-secondary education. Most reported being 
homosexual/gay (68%), never injecting drugs (94%), no STD diagnosis (81%), and having 
ever tested for HIV (90%). Three-quarters had sex with men only and the majority reported 
multiple male partners in the past year. Among the 59% who reported non-injected illegal 
drug use, marijuana was most common (89%), followed by cocaine (28%) and crack cocaine 
(20%). The majority had some form of health insurance and 81% had visited a doctor in the 
past year. Median time since last HIV test was 305 days.
Prevalence of HIV infection and associated factors
Prevalence of HIV infection by socioeconomic and behavioral characteristics is presented in 
Table 2 for both cross-sectional recruitment waves. In 2004–2005, 38% of participants tested 
HIV positive. HIV prevalence by race was 51% among Black MSM, 13% among non-
Hispanic White MSM, and 24% among other MSM of color. Table 3 shows the results of 
univariate and multivariate analyses of prevalent HIV infection for both waves of data 
collection. In the first wave, minority race, being older than 24 years, having nine or more 
partners, STD diagnosis, having public health insurance, and a doctor’s visit in the prior year 
were significantly and independently associated with being HIV positive. Older MSM were 
1.4–1.8 times more likely to be HIV positive compared to 18–24 year olds. Black MSM 
were approximately 3.7 times and other race MSM were 2.0 times more likely to be HIV 
positive than non-Hispanic White MSM.
In the second wave, 38% of participants overall, 45% of Black, 18.3% of non-Hispanic 
White MSM, and 25% of other men of color tested HIV positive. HIV infection was 
significantly and independently associated with Black race, UAI with casual or exchange 
male partners in the prior year (compared to no UAI), and prior STI diagnosis. Risk of being 
HIV positive among Black MSM was 2.5 times higher than among non-Hispanic White 
MSM.
Prevalence of Unrecognized HIV infection and associated factors
Prevalence of unrecognized HIV infection by socioeconomic and behavioral factors is 
shown in Table 2 for both cross-sectional recruitment waves. In the first wave, 58% of HIV 
positive MSM were unaware of their HIV positive serostatus at the time of enrollment. Of 
these, 57% reported their most recent test was negative, 20% did not obtain the results of 
their most recent test, 3% had a recent indeterminant test, less than 1% had never been 
tested, and 20% did not know results of their most recent test. The proportion unrecognized 
HIV infection was higher among younger men, from 38% among those 45 years or older to 
89% among those 18–24 years of age. By race, the proportion of unrecognized HIV 
infection ranged from 64% among Black men to 15% among non-Hispanic White 
participants.
Table 4 shows the results of univariate and multivariate analyses of characteristics associated 
with unrecognized HIV infection. In the first wave, unrecognized infection was higher 
among those who reported minority race/ethnicity, younger age, multiple partners, UAI with 
main partners, no STD diagnosis, no health insurance, and no doctor visit in the past year. In 
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multivariate analysis, minority race/ethnicity, decreasing age, having 2–3 partners (compared 
to 1), having no health insurance (compared to private insurance) and not visiting a doctor in 
past year were significantly associated with unrecognized HIV infection (Table 3). 
Controlling for these factors, Black MSM were 4 times as likely and other MSM of color 
were 3.5 times as likely to have unrecognized infection than non-Hispanic White MSM.
In the second wave (2008), 74% of HIV positive participants were unaware of their HIV 
positive serostatus. Among these, 67% reported their most recent test was negative, 15% did 
not obtain the results of their most recent test, 4% had a recent indeterminant test, 0% had 
never been tested, 5.7% did not know results of their most recent test, and 2.4% refused to 
answer. Seventy-seven percent of Black MSM did not know they were HIV positive, 
compared to 47% of non-Hispanic White MSM. None of the six HIV positive men of other 
race/ethnicity were aware of their HIV status. Unrecognized infection was significantly 
higher among men of other race/ethnicity and who had both male and female partners, but 
significantly lower among men over 45, those with public insurance (compared to no 
insurance), and those who had seen a doctor in the past year. In multivariate analysis, men 
over 45 and those who had visited a doctor in the past year were 35% less likely and 
approximately 20% less likely, respectively, to be unaware of their HIV infection.
Discussion
These results show high prevalence of HIV infection and unrecognized HIV infection among 
MSM in Baltimore in 2005 and 2008, particularly among men of color and young men. Two 
CDC reports have compared HIV prevalence and unrecognized infection rates among MSM 
in U.S. cities. In 2005, MSM in Baltimore had the highest HIV prevalence and undiagnosed 
infection rates compared to their counterparts in Los Angeles, Miami, San Francisco, and 
New York25 and, in 2008, rates in Baltimore exceeded those of 20 other high prevalence 
cities15. A recent study estimated that racial disparities in MSM HIV infection were highest 
in Maryland compared to 16 other southern states (Maryland Rate Ratio=7.1, p<0.001 vs 
Total: 4.6, p<0.001) 11. Although it is possible that the NHBS HIV prevalence rankings are 
confounded by racial differences across cities, the current study confirms the 
disproportionate HIV burden borne by Black and other minority MSM in Baltimore. There 
is a very real possibility that the HIV epidemic among MSM may further expand, 
particularly given the high levels of unrecognized infection among young MSM and UAI 
among men unaware of their HIV infection.
Despite the different demographic and behavioral compositions of these two recruitment 
waves, overall HIV prevalence was consistent. These findings corroborate reports of high 
HIV prevalence among MSM from other cities24 and expand on prior reports of pronounced 
racial disparity in HIV among young Baltimore MSM 17,18. Recent attention to HIV 
resurgence among U.S. MSM may not fully account for the historically high HIV prevalence 
among African-American MSM as observed in Baltimore. HIV infection in these studies 
among adult MSM was much higher than the in 1996–2000 YMS study among young MSM 
in Baltimore, which reported 12% prevalence overall and 27% among non-Hispanic 
blacks16. Yet the similarity in demographic and behavioral correlates of infection between 
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this study and the YMS findings suggests that there are persistent prevention needs in 
Baltimore.
Notably, the majority of men who tested HIV positive in both waves of data collection were 
not aware of their HIV status. Beginning in 2001, CDC recommended greater emphasis on 
finding undiagnosed HIV infections26 and later revised the recommendation to enhance 
testing in healthcare settings27. While the effectiveness and cost of this approach relative to 
other HIV testing policies has been debated28, the current study examined the burden of 
unrecognized HIV infection and racial disparities of unrecognized infections among MSM 
in Baltimore at two time points following these recommendations. The very high observed 
proportion of participants who were unaware of their HIV infection suggests that testing 
efforts are not adequately reaching MSM in Baltimore, particularly minority and young 
MSM, which in turn limits access to the benefits of HIV treatment and secondary 
prevention.
Known HIV infection was associated with a doctor visit, suggesting that clinical settings are 
feasible venues to target some MSM and may be effectively providing testing services. 
However, many primary healthcare providers miss opportunities to provide HIV testing29 
and counseling30. Given the high HIV prevalence rates and multiple risk behaviors, a diverse 
portfolio of HIV behavioral interventions along with routine testing and counseling will be 
needed to adequately meet the challenges of the current epidemic. This study utilized a 
structured venue-based sampling method to recruit participants. A similar methodology for 
outreach HIV testing efforts and other prevention programming may be viable for increasing 
service availability for Baltimore MSM.
These findings are subject to numerous limitations. Temporal relationships cannot be 
determined due to the cross-sectional design in both waves and temporal trend comparisons 
are not definitive, as they may be due to true differences or the recruitment of different 
samples. Differential enrollment bias may have occurred between the two waves. Although 
the study protocols were identical, qualitative differences in implementation may have 
occurred. The venue universe differed between waves and this may also have contributed to 
differences between the 2004–5 and 2008 samples. Demographic and HIV risk behavior data 
were self-reported, and therefore subject to misreporting due to recall or social desirability, 
concerns about stigma, or cultural differences. Some men who knew their HIV status to be 
positive may have reported negative status due to perceived stigma or concern about study 
eligibility, although materials clearly described eligibility and reinforced anonymity and staff 
members were trained in rapport-building and cultural sensitivity. Lack of disclosure due to 
stigma concerns may also be a barrier to partner disclosure and a worthy target of prevention 
efforts. Sexual behavior and drug use measures were summary measures, which may limit 
interpretation. Findings may not be generalizable to MSM who do not frequent study 
recruitment venues, who only frequent less well-attended venues, or do not reside in the 
Baltimore-Towson metropolitan area. There may also be residual bias and underestimation 
of uncertainty because the data were not weighted by venue attendance patterns and 
likelihood of recruitment.
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Despite limitations, these BESURE surveys provide a needed assessment of urban MSM and 
a useful foundation for future research and HIV prevention planning. That these two 
recruitment waves were demographically different but had similar epidemiological profiles 
suggests a broad need for prevention across the diverse population of Baltimore MSM. 
These surveys indicate that venue-based recruitment methods are feasible for reaching 
diverse MSM populations and may be useful for HIV testing and prevention programs. 
Given that demographic and behavioral characteristics did not alter the association between 
race/ethnicity and HIV status, it is likely that individual level explanations are insufficient to 
explain the observed disparities. Input from local community members, providers, and 
researchers points to the following to combat the strikingly pronounced epidemiological 
disparities observed here: culturally-sensitive health care and structural prevention 
approaches to reduce stigma and discrimination toward same-sex behavior and HIV 
infection; interventions that increase pro-condom use norms; prevention for positives; 
integration of prevention and medical care; and contextualized prevention strategies that 
address men who have sex with both women and men. It is imperative to implement 
interventions that are not only ethnically diverse but also ones that acknowledge and 
embrace the diversity of ethnic, sexual, and social identities and lifestyles among urban 
MSM.
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Figure 1. 
Recruitment for BESURE study among MSM in Baltimore, 2004–2005 and 2008
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Table 1
Sample composition of MSM in Baltimore, 2004–2005 (n=645) and 2008 (n=448)
Sample Characteristics
Socio-demographic and behavioral characteristics
Wave 1 (2004–2005) Wave 2 (2008) p-value
Total (Column %) Total (Column %)
Total 645 (100) 448 (100)
Socio-demographic
Race
 White 201 (31.16) 104 (23.21) 0.0040
 Black 403 (62.48) 320 (71.43) 0.0021
 Other 41 (6.36) 24 (5.36) 0.4920
Age
 < 24 years old 163 (24.27) 140 (31.25) 0.0299
 25–34 years old 166 (25.74) 135 (30.13) 0.1095
 35–44 years old 197 (30.54) 108 (24.11) 0.0197
 > 45 years old 119 (18.45) 65 (14.51) 0.0868
Current Homeless
 No 625 (96.90) 421 (93.97) 0.019
 Yes 20 (3.10) 27 (6.03) 0.019
Education
 High school education or less 316 (48.99) 217 (48.44) 0.8568
 College or some college 288 (44.65) 203 (45.31) 0.8288
 Graduate education 41 (6.36) 28 (6.25) 0.9432
Sexual Identity
 Homosexual 407 (63.10) 302 (67.71) 0.1164
 Bisexual 205 (31.78) 134 (30.04) 0.5420
 Heterosexual or other 33 (5.35) 10 (2.24) 0.0165
Sexual Behaviors
#male sex partners in last 12 months
 One (ref) 165 (25.58) 109 ( 24.33) 0.6388
 2 to 3 182 (28.22) 154 (34.38) 0.0300
 4 to 8 149 (23.10) 115 (25.67) 0.3291
 9 or more 149 (23.10) 70 (15.63) 0.0024
In past 12 months, any sex with:
 Men only 429 (66.51) 339 (75.67) 0.0011
 Men and women 216 (33.49) 109 (24.33) 0.0011
In past 12 months
 No UAI 304 (47.13) 286 (63.84) <.0001
 UAI with main partners only 164 (25.43) 80 (17.86) 0.0031
 UAI with casual/exchange partners 177 (27.44) 82 (18.30) 0.0005
Drug Use Behaviors
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Sample Characteristics
Socio-demographic and behavioral characteristics
Wave 1 (2004–2005) Wave 2 (2008) p-value
Total (Column %) Total (Column %)
Ever injected drugs
 No 534 (82.79) 421 (93.97) <.0001
 Yes 111 (17.21) 27 (6.03) <.0001
Non-injection drug use in last 12 months
 No 329 (51.01) 184 (41.07) 0.0012
 Yes 316 (48.99) 264 (58.93) 0.0012
Health History and Insurance
Ever been tested for HIV
 No 85 (13.18) 43 (9.62) 0.0722
 Yes 560 (86.82) 404 (90.38) 0.0722
Been told by MD had any STD:
 No 542 (84.03) 361 (80.58) 0.1516
 Yes 103 (15.97) 87 (19.42) 0.1516
Health insurance
 No health insurance (ref) 230 (36.28) 164 (37.19) 0.2767
 Public 146 (23.03) 84 (19.05) 0.2767
 Private 258 (40.69) 193 (43.76)
Visit a doctor’s office in last 12 months
 No 146 (22.64) 87 (19.42) 0.2017
 Yes 499 (77.36) 361 (80.58) 0.2017
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Table 2
Characteristics of BESURE MSM participants with HIV and unrecognized HIV infection, 2004–2005 and 
2008
Socio-demographic and behavioral characteristics
HIV positive Unrecognized HIV infection
2004–2005 2008 2004–2005 2008
n (row %) n (row %) n (row %) n (row %)
Total 243 (37.7) 168 (37.5) 142 (58.44) 125 (74.40)
Socio-demographic
Race Ethnicity
 Non-Hispanic White 26 (12.94) 19 (18.3) 4 (15.38) 9 (47.37)
 Non-Hispanic Black 207 (51.36) 143 (44.7) 132 (63.77) 110 (76.92)
 Other 10 (24.39) 6 (25.0) 6 (60.00) 6 (100.00)
Age
 < 24 years old 41 (25.15) 41 (29.3) 36 (87.80) 35 (85.37)
 25–34 years old 53 (31.93) 56 (41.5) 36 (67.92) 42 (75.00)
 35–44 years old 99 (50.25) 43 (39.8) 51 (51.52) 34 (79.07)
 > 45 years old 50 (42.02) 28 (43.1) 19 (38.00) 14 (50.00)
Current Homeless
 No 236 (37.76) 157 (37.3) 138 (58.47) 117 (74.52)
 Yes 7 (35.00) 11 (40.7) 4 (57.14) 8 (72.73)
Education
 High school education or less 139 (43.99) 91 (41.9) 86 (61.87) 68 (74.73)
 College or some college 98 (34.03) 69 (34.0) 54 (55.10) 53 (76.81)
 Graduate education 6 (14.63) 8 (28.6) 2 (33.33) 4 (50.00)
Sexual Identity
 Homosexual 167 (41.03) 119 (39.4) 95 (56.89) 86 (72.27)
 Bisexual 63 (30.73) 47 (35.1) 39 (61.90) 38 (80.85)
 Heterosexual or other 13 (39.39) 2 (20.0) 8 (61.54) 1 (50.00)
Sexual Behaviors
Number of male sex partners last 12 months
 One (ref) 52 (31.52) 37 (33.9) 22 (42.31) 28 (75.68)
 2 to 3 72 (39.56) 54 (35.1) 49 (68.06) 40 (74.07)
 4 to 8 51 (34.23) 50 (43.5) 32 (62.75) 38 (76.00)
 9 or more 68 (45.64) 27 (38.6) 39 (57.35) 19 (70.37)
In past 12 months, any sex with:
 Men only 175 (40.79) 135 (39.8) 97 (55.43) 96 (71.11)
 Men and women 68 (31.48) 33 (30.3) 45 (66.18) 29 (87.88)
In past 12 months
 No UAI 108 (35.53) 99 (34.6) 58 (53.70) 72 (72.73)
 UAI with main partners only 55 (33.54) 26 (32.5) 40 (72.73) 21 (80.77)
 UAI with casual/exchange partners 80 (45.20) 43 (52.4) 44 (55.00) 32 (74.42)
Drug Use Behaviors
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Socio-demographic and behavioral characteristics
HIV positive Unrecognized HIV infection
2004–2005 2008 2004–2005 2008
n (row %) n (row %) n (row %) n (row %)
Ever injected drugs
 No 199 (37.27) 160 (38.0) 120 (60.30) 118 (73.75)
 Yes 44 (39.64) 8 (29.6) 22 (50.00) 7 (87.50)
Injection drug use last 12 months
 No 232 (38.60) 167 (38.0) 134 (58.01) 124 (74.25)
 Yes 11 (25.00) 1 (12.5) 7 (63.64) 1 (100)
Non-injection drug use last 12 months
 No 122 (37.08) 61 (33.2) 67 (54.92) 48 (78.69)
 Yes 121 (38.29) 107 (40.5) 75 (61.98) 77 (71.96)
Health History and Insurance
Ever been tested for HIV
 No 30 (35.29) 15 (34.9) 30 (100.00) 15 (100.00)
 Yes 213 (38.04) 152 (37.6) 112 (52.58) 109 (71.71)
Been told by MD had any STD:
 No 188 (34.76) 124 (34.4) 115 (61.50) 96 (77.42)
 Yes 55 (53.40) 44 (50.6) 26 (47.27) 29 (65.91)
Health insurance
 No health insurance (ref) 73 (31.74) 66 (40.2) 54 (73.97) 53 (80.30)
 Public 85 (58.22) 40 (47.6) 40 (47.06) 29 (72.50)
 Private 79 (30.62) 60 (31.1) 44 (55.70) 41 (68.33)
Visit a doctor’s office in last 12 months
 No 38 (26.03) 29 (33.3) 34 (89.47) 27 (93.10)
 Yes 205 (41.08) 139 (38.5) 108 (52.68) 98 (70.50)
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Table 3
Predictors of positive HIV status among MSM in Baltimore BESURE study 2004–2005 (n=645) and 2008 
(n=448)
Socio-demographic and 
behavioral characteristics
Wave 1 (2004–2005) HIV positive Wave 2 (2008) HIV positive
Unadjusted PR (95% 
CI)
Adjusted PR (95% 
CI)a
Unadjusted PR (95% 
CI)
Adjusted PR (95% 
CI)a
Socio-demographic
Race Ethnicity
 Non-Hispanic White 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Non-Hispanic Black 3.97 (2.27–6.96) 3.70 (2.24–6.12) 2.45 (1.49–4.01) 2.46 (1.53–3.96)
 Other 1.89 (0.95–3.76) 1.95 (1.03–3.71) 1.37 (0.53–3.56) 1.32 (0.52–3. 35)
Age
 < 24 years old 1.0 (ref) 1.0 (ref) 1.0 (ref)
 25–34 years old 1.27 (0.97–1.66) 1.37 (1.04–1.80) 1.42 (0.96–2.08)
 35–44 years old 2.00 (1.53–2.61) 1.76 (1.39–2.22) 1.35 (0.95–1.95)
 > 45 years old 1.67 (1.18–2.36) 1.76 (1.39–2.22) 1.47 (0.93–2.32)
Current Homeless
 No 1.0 (ref) 1.0 (ref)
 Yes 0.93 (0.54–1.50) 1.09 (0.63–1.89)
Education
 Graduate education 1.0 (ref) 1.0 (ref)
 College or some college 3.01 (1.52–5.95) 1.19 (0.61–2.31)
 High school education or less 2.33 (1.11–4.88) 1.47 (0.66–3.22)
Sexual Identity
 Homosexual 1.0 (ref) 1.0 (ref)
 Bisexual 0.75 (0.52–1.07) 0.89 (0.66–1.20)
 Heterosexual or other 0.96 (0.68–1.35) 0.51 (0.18–1.45)
Sexual Behaviors
# of male sex partners last 12 months
 One (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 2 to 3 1.26 (0.91–1. 72) 1.23 (1.00–1.51) 1.03 (0.78–1.36)
 4 to 8 1.09 (0.73–1.60) 1.12 (0.83–1.52) 1.28 (0.96–1.72)
 9 or more 1.45 (1.12–1.87) 1.31 (1.07–1.61) 1.14 (0.67–1.93)
In past 12 months, any sex with:
 Men only 1.0 (ref) 1.0 (ref)
 Men and women 0.77 (0.59–1.01) 0.76 (0.53–1.10)
In past 12 months
 No UAI 1.0 (ref) 1.0 (ref) 1.0 (ref)
 UAI with main partners only 0.94 (.75–1.19) 0.94 (0.62–1.42) 0.89 (0.57–1.38)
 UAI with casual/exchange 
partners
1.27 (.94–1.72) 1.51 (1.10–2.09) 1.43 (1.05–1.95)
Drug Use Behaviors
Ever injected drugs
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Socio-demographic and 
behavioral characteristics
Wave 1 (2004–2005) HIV positive Wave 2 (2008) HIV positive
Unadjusted PR (95% 
CI)
Adjusted PR (95% 
CI)a
Unadjusted PR (95% 
CI)
Adjusted PR (95% 
CI)a
 No 1.0 (ref) 1.0 (ref)
 Yes 1.06 (0.75–1.52) .78 (0.46–1.32)
Injection drug use last 12 months
 No 1.0 (ref) 1.0 (ref)
 Yes 0.65 (0.26–1.64) 0.33 (0.05–2.23)
Non-injection drug use last 12 months
 No 1.0 (ref) 1.0 (ref)
 Yes 1.03 (0.85–1.25) 1.23 (0.94–1.59)
Health History and Insurance
Ever been tested for HIV
 No 1.0 (ref) 1.0 (ref)
 Yes 1.08 (0.76–1.54) 1.07 (0.71–1.64)
Been told by MD had any STD:
 No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Yes 1.53 (1.26–1.88) 1.23 (1.06–1.42) 1.47 (1.14–1.89) 1.47 (1.17 – 1.84)
Health insurance
 No health insurance (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Public 1.83 (1.15–2.39) 1.32 (1.05–1.66) 1.18 (0.93–1.51)
 Private 0.96 (0.66–1.41) 1.10 (0.81–1.50) 0.77 (0.59–1.04)
Visit a doctor’s office in last 12 months
 No 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Yes 1.58 (1.20–2.07) 1.43 (1.03–1.96) 1.16 (0.86–1.56)
aAll variables with p < .05 in the univariate analysis were included in the log-binomial model.
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Table 4
Predictors of unrecognized HIV infection among HIV-positive MSM in Baltimore BESURE study 2004–2005 
(n=142) and 2008 (n=125)
Socioeconomic and behavioral 
characteristics
Wave 1 (2004–2005) Unrecognized HIV 
infection Wave 2 (2008) Unrecognized HIV infection
Unadjusted PR (95% 
CI)
Adjusted PR (95% 
CI)a
Unadjusted PR (95% 
CI)
Adjusted PR 
(95% CI)a
Socioeconomic
Race Ethnicity
 Non-Hispanic White 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Non-Hispanic Black 4.14 (1.88–9.13) 3.95 (1.92–8.15) 1.62 (0.95–2.76) 1.39 (.89–2.19)
 Other 3.90 (1.58–9.61) 3.48 (1.68–7.21) 2.11 (1.25–3.55) 1.51 (.96–2.40)
Age
 < 24 years old 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 25–34 years old 0.77 (0.63–0.96) 0.88 (0.84–0.93) 0.88 (0.70–1.11) 0.92 (0.83–1.02)
 35–44 years old 0.59 (0.48–0.72) 0.75 (0.64–0.88) 0.93 (0.73–1.18) 0.92 (0.83–1.03)
 > 45 years old 0.43 (0.25–0.75) 0.55 (0.37–0.84) 0.59 (0.41–0.84) 0.65 (0.45–0.93)
Current Homeless
 No 1.0 (ref) 1.0 (ref)
 Yes 0.98 (0.47–2.01) 0.98 (0.70–1.36)
Education
 Graduate education 1.0 (ref) 1.0 (ref)
 College or some college 1.09 (0.88–1.34) 1.53 (.82–2.87)
High school education or less 1.08 (0.68–1.72) 1.49 (0.82–2.73)
 Sexual Identity
 Homosexual 1.0 (ref) 1.0 (ref)
 Bisexual 1.09 (0.86–1.38) 1.12 (.98–1.28)
 Heterosexual or other 1.08 (0.69–1.70) .69 (.17–2.83)
Sexual Behaviors
# male sex partners last 12 mos
 One (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 2 to 3 1.61 (1.12–2.31) 1.48 (1.10–1.98) .98 (0.78–1.23)
 4 to 8 1.48 (1.00–2.18) 1.30 (0.98–1.73) 1.00 (0.79–1.27)
 9 or more 1.36 (0.93–1.97) 1.30 (0.98–1.73) .93 (0.68–1.27)
In past 12 months, any sex with:
 Men only 1.0 (ref) 1.0 (ref)
 Men and women 1.19 (0.99–1.48) 1.24 (1.08–1.41)
In past 12 months
 No UAI 1.0 (ref) 1.0 (ref)
 UAI with main partners only 1.35 (1.08.–1.70) 1.11 (.88–.1.40)
 UAI with casual/exchange partners 1.02 (0.80–1.30) 1.02 (.85–1.23)
Drug Use Behaviors
Ever injected drugs
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Socioeconomic and behavioral 
characteristics
Wave 1 (2004–2005) Unrecognized HIV 
infection Wave 2 (2008) Unrecognized HIV infection
Unadjusted PR (95% 
CI)
Adjusted PR (95% 
CI)a
Unadjusted PR (95% 
CI)
Adjusted PR 
(95% CI)a
 No 1.0 (ref) 1.0 (ref)
 Yes .83 (.59–1.16) 1.19 (0.92–1.54)
Injection drug use last 12 months
 No 1.0 (ref) 1.0 (ref)
 Yes 1.10 (.75–1.60) 1.17 (0.86–1.58)
Non-injection drug use last 12 months
 No 1.0 (ref) 1.0 (ref)
 Yes 1.13 (0.87–1.46) 0.91 (0.79–1.05)
Health History and Insurance
Been told by MD had any STD:
 No 1.0 (ref) 1.0 (ref)
 Yes 0.77 (0.61–.97) 0.85 (0.67–1.10)
Health insurance
 No health insurance (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Public 0.64 (0.49–0.83) 0.84 (0.68–1.03) 0.91 (0.73–.99)
 Private 0.75 (0.55–1.02) 0.88 (0.84–0.93) 0.90 ( 0.70–1.16)
Visit doctor’s office last 12 mos
 No 1.0 (ref) 1.0 (ref) 1.0 (ref) 1.0 (ref)
 Yes 0.59 (0.50–0.70) 0.88 (0.84–0.93) 0.76 (0.63–0.91) 0.82 (0.71–0.94)
aAll variables with p < .05 in the univariate analysis were included in the log-binomial model
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